Esperion Therapeutics ESPR is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Esperion Therapeutics will report an earnings per share (EPS) of $-0.16.
Investors in Esperion Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Historical Earnings Performance
Last quarter the company missed EPS by $0.06, which was followed by a 10.72% drop in the share price the next day.
Here's a look at Esperion Therapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.15 | -0.16 | -0.18 | -0.15 |
| EPS Actual | -0.21 | -0.11 | -0.15 | -0.05 |
| Price Change % | -11.0% | -7.000000000000001% | 8.0% | -2.0% |
Esperion Therapeutics Share Price Analysis
Shares of Esperion Therapeutics were trading at $1.4 as of August 01. Over the last 52-week period, shares are down 25.87%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Esperion Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
